Catalog No.
YHK66101
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ser717-Gly1054
Predicted molecular weight
41.57 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q9NYV4
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CrkRS, CRK7, Cell division protein kinase 12, KIAA0904, Cyclin-dependent kinase 12, CDC2-related protein kinase 7, CRKRS, CDK12, hCDK12, Cell division cycle 2-related protein kinase 7, Cdc2-related kinase, arginine/serine-rich
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma., PMID:40504161
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12., PMID:40389480
PAF1C-mediated activation of CDK12/13 kinase activity is critical for CTD phosphorylation and transcript elongation., PMID:40315851
A crucial role of miR-155 in the pathomechanism of acute kidney injury., PMID:40308762
[Clinicopathological features of primary thoracic synovial sarcoma: a study of 42 cases]., PMID:40302578
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells., PMID:40298170
DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition., PMID:40295725
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer., PMID:40267193
PIN1-SUMO2/3 motif suppresses excessive RNF168 chromatin accumulation and ubiquitin signaling to promote IR resistance., PMID:40229270
Dynamic O-GlcNAcylation and phosphorylation attract and expel proteins from RNA polymerase II to regulate mRNA maturation., PMID:40186208
Absence of CDK12 in oocyte leads to female infertility., PMID:40148269
SSUP-72/PINN-1 coordinates RNA-polymerase II 3' pausing and developmental gene expression in C. elegans., PMID:40097442
Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition., PMID:40080446
Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma., PMID:40056603
Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12/13., PMID:39955845
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors., PMID:39948720
Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors., PMID:39895499
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis., PMID:39848867
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer., PMID:39847876
Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer., PMID:39806366
Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors., PMID:39793578
Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study., PMID:39755215
Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC., PMID:39754574
Novel structural variants that impact cell cycle genes are elucidated in metastatic gastrointestinal stromal tumors., PMID:39708519
Quest for discovering novel CDK12 inhibitor., PMID:39697035
Roles of CDK12 mutations in PCa development and treatment., PMID:39681197
The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence., PMID:39626031
CDK12 antagonizes a viral suppressor of RNAi to modulate antiviral RNAi in Drosophila., PMID:39601580
Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database., PMID:39570378
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer., PMID:39558146
Physiological and pathological roles of the transcriptional kinases CDK12 and CDK13 in the central nervous system., PMID:39533070
Discovery and design of molecular glue enhancers of CDK12-DDB1 interactions for targeted degradation of cyclin K., PMID:39450271
CDK-dependent phosphorylation regulates PNKP function in DNA replication., PMID:39395804
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader., PMID:39388374
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13., PMID:39368479
Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase., PMID:39361894
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition., PMID:39353441
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors., PMID:39321214
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial., PMID:39293514
Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA., PMID:39270556
Role of specific CDKs in regulating DNA damage repair responses and replication stress., PMID:39265226
Quantum Chemical Characterization of Rotamerism in Thio-Michael Additions for Targeted Covalent Inhibitors., PMID:39265068
Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer., PMID:39247812
Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy., PMID:39186062
Elucidating the Selective Mechanism of Drugs Targeting Cyclin-Dependent Kinases with Integrated MetaD-US Simulation., PMID:39172502
Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer., PMID:39172235
CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts., PMID:39155303
Cryo-EM structure of the CDK2-cyclin A-CDC25A complex., PMID:39122719
Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex., PMID:39090085
CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma., PMID:39082894
For research use only. Not for human or drug use.
